We’ve supported more than 150 infectious disease studies, leading to the approval of 13 important marketed products.
Our accomplishments in program management and drug development in infectious diseases (ID) are clear to see. More than 60% of our Project Management and Clinical Operations staff have experience in ID clinical research, and we’ve conducted studies across a wide range of indications in vaccines, antibacterials, antivirals, antifungals, pneumonia, and antiparasitics.
PHASE I-IV CLINICAL STUDIES150+
Leveraging our experience, medical informatics, and real-time data for real results.
Our analytical informatics tools supplement our therapeutic expertise and practical experience with data derived from the lab, pharmacy, EMR, diagnostic, and other databases. We provide data related to natural disease histories, study protocol optimization, and contextual informatics for site selection or enrichment of site-specific populations.
We also gather real-time survey data to identify suitable regions and appropriate sites and patient populations, combining existing available data like investigator metrics and study performance with direct investigator feedback to minimize study start-up time. Our familiarity with ID investigators worldwide, as well as our knowledge of disease incidence and prevalence, facilitate optimal site and patient selection, and our access to the US claims data enables us to identify optimal investigator locations and patient volume.Discover how we’re overcoming recruitment challenges to meet enrollment goals.
Supporting sponsors in key areas of infectious diseases.
We’ve run 110 antiviral studies totaling more than 63,600 patients for Hepatitis C, HIV, and Hepatitis B. Our antibacterial expertise includes bacterial infection, intra-abdominal, skin/soft tissue infection, and urinary infection.
Vaccine & Regional Knowledge Critical to Rescue of Hepatitis B Vaccine Study
A case study describing the rescue of a hepatitis B vaccine study.
Early Engagement Crucial to Develop Trial Design for Accelerated Schedule Vaccine Study
A case study describing PRA's involvement in an accelerated schedule vaccine study for poliomyelitis.
Discovering the People Behind the Science: Dr. Aimee Payne
Rare Diseases Advisory Committee Members
Creating Solutions to Ensure Endpoint Protection in Challenging Rare Disease Trial
The collection of high-quality endpoint data was paramount to the success of this Phase II program. Because this was the first clinical trial ever…